Navigation Links
Astra Tech Acquires an Innovative Dental CAD/CAM Company
Date:9/27/2007

les in 2008 are expected to reach USD 25 million.

"Astra Tech with its focus on research and its global sales organization is the perfect owner for Atlantis as it offers the ideal environment within which to further develop Atlantis' unique technology as well as grow the business," says Bob Stockard, CEO, Atlantis.

Operations will be integrated within Astra Tech's North American headquarter in Waltham, Massachusetts. The North American market represents approximately one third of the world market, and is Astra Tech's most important one. It is currently one of the fastest growing markets for the Astra Tech Group.

"The two companies complement each other perfectly. Through the acquisition of Atlantis, we can offer all dentists working with implants an optimal solution, in terms of both esthetics and function," says Scott Root, President and CEO, Astra Tech Inc., North America.

"We will develop a Center of Excellence in the US for esthetics, based on Atlantis' unique know-how and technology in order to offer advanced innovative digital dentistry solutions," says Peter Selley.

In 2008, Astra Tech will begin producing Atlantis' CAD/CAM abutments for the European market at its headquarters in Molndal, Sweden. The launch and sales in Europe will be handled by Astra Tech's existing sales organization.

As recently as June of this year, Astra Tech opened a new training center at its headquarters in Molndal, where dental professionals from all over the world are invited there to study the latest implant technology.

Astra Tech, a subsidiary of the AstraZeneca Group, develops, manufactures, and markets dental implants and advanced disposable medical equipment for the healthcare sector. The company develops products that lead to improved treatment results, simplified work for healthcare personnel, and which contribute to reducing healthcare costs.

Astra Tech's headquarters and production facilities are located in Molndal, Sweden. Th
'/>"/>

SOURCE Astra Tech
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Ayurvastra Initiative Launched
2. Astra Zenecas Seroquel Gets FDA Approval For Schizophrenia
3. Astrazenecas Investigational Cancer Therapies Revealed at ASCO
4. Ossur Acquires the U.S. Orthopaedics Company
5. Stem of Hope: Stem Cell Research Acquires a Brittle Star As A model
6. Pfizer Acquires Worldwide Rights For New Overactive Bladder Drug
7. Premier Army Hospital Acquires PET-CT Scanner
8. Wockhardt acquires Protinex, Farex brands from Netherland Co
9. Indoco Remedies Acquires La Nova Chem
10. Ranbaxy Acquires Glaxosmithklines Generic Unit in Spain
11. AIIMS Acquires Four-Armed Robot to Assist in Surgeries
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Reportlinker Adds Radiation Therapy Equipment - A Global Market Review 2Reportlinker Adds Radiation Therapy Equipment - A Global Market Review 3Reportlinker Adds Radiation Therapy Equipment - A Global Market Review 4Reportlinker Adds Radiation Therapy Equipment - A Global Market Review 5Reportlinker Adds Radiation Therapy Equipment - A Global Market Review 6Reportlinker Adds Radiation Therapy Equipment - A Global Market Review 7Reportlinker Adds Radiation Therapy Equipment - A Global Market Review 8Particle Sciences and IES Engineers Cooperate on High Potency Compound Handling Capabilities 2Particle Sciences and IES Engineers Cooperate on High Potency Compound Handling Capabilities 3Global Announces Contract To Acquire New Business 2Wound Management Technologies Inc Announced Today That It Has Reached an Agreement in Principal to Acquire BioPharma Management Technologies Inc 12648 1Wound Management Technologies Inc Announced Today That It Has Reached an Agreement in Principal to Acquire BioPharma Management Technologies Inc 12648 2Carbon Design Innovations Inc Introduces Carbon Nanotube Probe Technology for Atomic Force Microscopy CNT Probes Deliver New Level of AFM Imaging P 12645 1Carbon Design Innovations Inc Introduces Carbon Nanotube Probe Technology for Atomic Force Microscopy CNT Probes Deliver New Level of AFM Imaging P 12645 2Carbon Design Innovations Inc Introduces Carbon Nanotube Probe Technology for Atomic Force Microscopy CNT Probes Deliver New Level of AFM Imaging P 12645 3Finances Trigger American Reluctance to Spend More on Healthier Foods 49018 1Finances Trigger American Reluctance to Spend More on Healthier Foods 49018 2
Other Medicine Technology:Biomira Selects PX-866 as Clinical Development Candidate and,Presents Promising Preclinical Data at AACR 2Biomira Selects PX-866 as Clinical Development Candidate and,Presents Promising Preclinical Data at AACR 3Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 2Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 3Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 4Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 5Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 6Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 7Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 8Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 9